What are the common side effects of Survodutide?

In phase 2 trials, the most common side effects of survodutide seen were GI-related and include nausea, vomiting, diarrhea, constipation and indigestion. These GI side effects were reported by 55% of people in the diabetes trial taking survodutide. This was compared to 28% of people taking semaglutide and 22% of the placebo group.

In the obesity trial, these GI side effects were reported by 75% of those taking survodutide, compared to 43% taking a placebo. The incidence of serious adverse events was similar between the 2 groups. There were 2 cases of dehydration that led to renal failure and 1 case of angioedema in this trial. Survodutide was associated with increase in heart rate. However, no arrhythmias or major cardiovascular events were reported in the survodutide group.

Treatment discontinuation because of side effects occurred in 15.9% of patients with type 2 diabetes receiving survodutide, 5.1% with placebo and 4.0% with semaglutide. In the obesity study, discontinuation rates were 25% and 4% with survodutide and placebo, respectively. The majority of these happened in the first 6 weeks of the study during drug escalation phase and were mainly attributed to GI side effects.

Source

• Nasser Mikhail, Soma Wali, (2024), Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes, J. Endocrinology and Disorders, 8(3): DOI:10.31579/2640-1045/184. Accessed June 7, 2025.